

Suggested Admission Orders for Patients Presenting with Hyperleukocytosis and Leukostasis

Hyperleukocytosis is seen in the setting of acute leukemia and is usually defined by a WBC > 100×10^9 /L. Leukostasis refers to the end-organ damage and tissue hypoxia that occur as a consequence of the high WBC count and most commonly manifests as respiratory symptoms or acute neurologic symptoms. **Hyperleukocytosis and leukostasis are medical emergencies requiring immediate initiation of cytoreductive therapy.** They can also be complicated by disseminated intravascular coagulation (DIC) and tumor lysis syndrome (TLS).

Bloodwork:
☐ Q6H: Electrolytes (Na, K, Cl, Ca, Mg, PO4), creatinine, uric acid
☐ Q6H: CBC, INR, fibrinogen
☐ Blood cultures, urine cultures
☐ Send uric acid sample on ice in patients who have received rasburicase
Cytoreductive Therapy:
☐ Hydroxyurea mg times per day
☐ Additional chemotherapy as per Oncology orders
* Leukapheresis may also be used to lower the WBC in some centers. However, there is no proven mortality benefit*
IV Fluids:
☐ Ringers Lactate at mL/hour
☐ Normal saline at mL/hour
 Avoid diuretics unless clinically significant volume overload is present (i.e., pulmonary edema requiring increased oxygen)
Transfusion Thresholds:
Maintain platelets greater than the following target:
☐ Not actively bleeding: 20 x 10 ⁹ /L
☐ Actively bleeding: 50 x 10 ⁹ /L
Maintain fibrinogen greater than 1-1.5 g/dL
☐ Maintain INR less than 2.0
Avoid PRBC transfusions unless the patient develops symptomatic anemia
Tumor Lysis Prophylaxis:
Rasburicase 4.5g IV x 1 with daily reassessment (after G6PD screening)



Imaging:	
☐ Chest x-	ray: All patients
CT brain	: All patients with neurologic symptoms, including altered level of consciousness
☐ CT ches	t: Consider if respiratory symptoms present
Additional Consid	derations:
☐ Conside	r empiric antibiotics for possible superimposed infection
Discuss	dexamethasone administration with the Oncology team
o T	nis may be added for respiratory failure, particularly in acute myelomonocytic leukemia (AMML)
☐ Sequen	ial compression device (SCD) for venous thromboembolism prophylaxis.